Delivery Order SPE2DB25D3006-SPE2DB25FXKFE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on August 20, 2025, carries a ceiling value of $13,968.50 and is scheduled for completion by September 11, 2025. The contract was competitively awarded without a set-aside designation, with performance taking place at AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based therapeutic product used for medical applications. This non-set-aside, competitively awarded contract is issued under a firm fixed price structure with an ultimate completion date of September 19, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on March 18, 2025, is scheduled for completion by April 8, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation,...
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications in military and federal healthcare settings. This $15,792.14 firm fixed-price contract, awarded on June 18, 2025, is classified as a non-set-aside competitive award with an ultimate completion date of July 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $30,878.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This non-set-aside contract, issued on September 17, 2025, with completion targeted for October 8, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). The IDC, valued at...
- The Defense Logistics Agency awarded a $14.4K delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used in medical and therapeutic applications. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by October 7, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The contract, awarded on June 17, 2025, is a firm fixed-price delivery order with a completion date of July 10, 2025, and involves no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 delivery order for Xeomin 100 Unit Vials, a botulinum toxin product used for medical purposes. This competitive award, issued on August 25, 2025, carries an ultimate completion date of September 16, 2025, and utilizes firm fixed pricing with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The award, issued on August 21, 2025, with an ultimate completion date of September 12, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major...
- SPE2DB25D3006Indefinite Delivery Contract
- SPE2DB25D3006-SPE2DB25FXKFEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic applications in military and veteran healthcare settings. This firm fixed-price delivery order, valued at $2,514.33, was competitively awarded without set-aside provisions and is scheduled for completion by September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performance location for this pharmaceutical supply. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime vendor for the Defense Logistics Agency's global pharmaceutical supply network, AmerisourceBergen leverages this comprehensive IDC vehicle to fulfill diverse medical procurement requirements for military healthcare programs, the Defense Health Agency, and other federal healthcare systems. The company's extensive portfolio of federal pharmaceutical contracts demonstrates its capability to deliver a wide range of medications and medical supplies through open competition and firm fixed-price arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 8/26/25 |